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Abstract 
 
 
Platinum-based chemotherapy remains the standard-of-care for most patients affected by advanced non-
small cell lung cancer (NSCLC). The platinum compounds currently used in NSCLC are cisplatin and 
carboplatin. The availability of new generation drugs has led to the adoption of schedules with lower doses 
of platinum compounds leading to increased tolerability. Several data suggest that third generation 
cisplatin-based regimens are slightly superior to carboplatin-based chemotherapy, with a different safety 
profile, and so cisplatin should remain the standard reference for the treatment of selected patients with 
advanced NSCLC. Recent evidence emphasized that the optimal number of first-line platinum cycles should 
be four for any NSCLC histology. New platinum compounds and the use of functional genomics to deliver 
platinum drugs as personalised medicine, are being investigated. Here we review the current status of 
cisplatin and carboplatin regimens looking to the future role of platinum compounds in advanced NSCLC 
patients. 
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INTRODUCTION 
Cisplatin, or cis-diamminedichloroplatinum (II), was the first platinum compound approved for use in 1978. 
Since then several platinum drugs have entered clinical trials, with two, carboplatin, or cis-diammine-
cyclobutanedicarboxylato platinum (II), and oxaliplatin, or 1,2-diaminocyclohexaneoxalato platinum (II), 
approved for cancer therapy worldwide. Platinum drugs are used to treat a wide variety of cancers, 
including non-small-cell lung cancer (NSCLC). The cytotoxic effects of platinum drugs are induced by 
targeting nuclear DNA. They form adducts preferentially with the N7 atom on guanine and adenosine 
bases. Such binding stops DNA replication and transcription, which then initiates cellular apoptosis [1]. 
NSCLC accounts for about 85% of all new lung cancer diagnoses which are around 1,8 million worldwide 
every year [2]. Since most patients with NSCLC have advanced disease at diagnosis, chemotherapy is the 
mainstay of management. In clinical practice, platinum-based regimens are the most widely used in the 
treatment of advanced NSCLC since meta-analyses showed a median overall survival (OS) improvement for 
cisplatin-based chemotherapy versus best supportive care [3, 4], or versus single-agent [5], in this setting. 
Another meta-analysis investigated the role of adding a third agent to platinum-based doublets and 
showed that triplets are associated with an increase in objective response rate (ORR) which does not 
translate in a better progression-free survival (PFS) or OS rate but with an increased toxicity [6].  
Living in the era of personalised medicine, the determination of oncogene-addicted NSCLC, mainly due to 
the presence of epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma 
kinase (ALK) and proto-oncogene tyrosine-protein kinase ROS (ROS1) translocations, is of paramount 
importance to select patients who can benefit by the use of correspondent inhibitors. However, the 
percentage of Caucasian patients with advanced NSCLC harbouring these alterations is as high as 20%, 
meaning that in the most of cases platinum-doublets represent the standard-of-care of the first-line 
therapy.   
In this paper, we review the current status of cisplatin and carboplatin regimens which are those used in 
the clinical practice for the management of NSCLC patients. 
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CONCERNS IN THE USE OF CISPLATIN AND CARBOPLATIN 
Platinum compounds attack, indiscriminately, all rapidly dividing cells leading to severe side effects and 
inducing the ability of cancers to develop drug resistance [1]. Common side effects of cisplatin and 
carboplatin include nausea and vomiting, myelosuppression, neuropathy, ototoxicity, hepatotoxicity and 
nephrotoxicity.  
Cisplatin is one of the most emetogenic drugs used, with considerable variability between individuals. 
Systematic use of a three-drug combination of a neurokinin 1 receptor antagonist, a 5-hydroxytryptamine-3 
(5-HT3) receptor antagonist, and dexamethasone improves control of acute emesis, but control of delayed 
emesis is often suboptimal [7]. Anemia can also occur during treatment with cisplatin. Several mechanisms 
can led to anemia, including depletion of intrinsic erythropoietin production (caused by peritubular renal 
cell depletion), reduced bone marrow stem cell activity and the absence of the stem cell reaction to 
administered erythropoietin [8-10]. The use of erythropoiesis-stimulating agents, when hemoglobin level is 
less than 10 g/dL, might help but it should be discussed with the patient to evaluate potential risks, such as 
thromboembolism, and benefits, such as decreased transfusions [11]. Nephrotoxicity may be reduced but 
not suppressed by hyper-hydration which, however, is not possible in patients with congestive heart 
failure, a comorbidity often present in patients with NSCLC [12, 13]. Peripheral neurotoxicity is the most 
common dose-limiting problem associated with modern cisplatin therapy. Cisplatin neurotoxicity, 
characterized by painful paresthesias and numbness, generally occurs during the first cycles. Loss of 
vibration sense, paraesthesia and ataxia can become apparent after several treatment cycles. Ototoxicity 
caused by cisplatin tends to be cumulative and can be irreversible, therefore monitoring by audiograms 
should be considered. Several therapeutic approaches have been developed and are under investigation to 
reduce or prevent these effects with very contrasting results [14]. 
Many of the side effects associated with cisplatin are less common with carboplatin, which is associated 
with risk of nephrotoxicity only when administered at high doses. However, carboplatin is not free of 
potentially relevant toxicities, because it causes dose-limiting myelosuppression, and also transient rises in 
bilirubin levels were observed [14, 15]. 
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In some patients, the side effects associated with the use of cisplatin or carboplatin can be so severe to 
determine dose reduction. These dose reductions, could increase the chance to develop resistance by 
cancer cells [16]. However, resistance is frequent also in patients who receive the full dose. A better 
understanding of the mechanisms associated with platinum resistance could help to improve the prognosis 
of many cancer patients. To date, four main mechanisms able to induce platinum resistance have been 
identified, including: (i) reduced cellular uptake of the platinum salt; (ii) increased repair of platinum-
induced DNA damage; (iii) degradation and detoxification of the drugs inside the cells by glutathione; and 
(iv) altered apoptosis [17, 18]. The resistance to platinum drugs has been studied extensively in vitro but, 
the clinical relevance of each of the above listed mechanisms is currently not entirely clear.  
The low therapeutic index of both cisplatin and carboplatin, that implies a careful evaluation of the balance 
between the risk of toxicity and the chance of clinical benefit, should be particularly considered when 
treating two special groups of NSCLC patients: the elderly subjects and those who are unfit but still eligible 
for active treatment. Approximately 50% of new lung cancer cases are diagnosed in patients aged more 
than 70 years, and about 15% in patients aged more than 80 years [19]. Aging may be associated with 
decreased physiologic reserve, comorbidity and polypharmacy, functional dependence, and inadequate 
social support, which lead to limited life expectancy with a potential reduced tolerance to cancer 
chemotherapy [20]. Furthermore, elderly patients are underrepresented in clinical trials and many 
treatment decisions are based on results of trials conducted in substantially younger individuals [21]. 
However, according to major international guidelines, age alone should not represent a barrier to best 
treatment, and fit elderly patients should be considered for standard platinum-based doublets. According 
to Eastern Cooperative Oncology Group (ECOG) scale, patients with performance status 2 (PS 2) are those 
who stay in bed, but for less than 50% of their daily time. It is crucial for clinicians to understand the reason 
why that patient is unfit and limited in daily activities: is it due to cancer symptoms or to comorbidities? Of 
note, a meta-analysis pooled the data of PS 2 patients coming from 6 randomized trials, for a total of 741 
subjects. This pooled analysis showed a significant improvement in ORR (odds ratio [OR] 3.243, 95% 
confidence interval [CI]: 1.883-5.583) and 1-year OS (OR 1.743, 95% CI: 1.203–2.525) in favour of platinum-
D
ow
nl
oa
de
d 
by
 [M
as
sim
o D
i M
aio
] a
t 1
0:5
4 2
8 M
arc
h 2
01
6 
6 
 
based doublets but, with higher incidence of grade 3-4 hematological toxicities [22]. These results suggest 
that in selected PS 2 NSCLC patients platinum-combination regimens are superior to single-agent. Thus, in 
both elderly and unfit subjects, if the patient is considered suitable for standard therapy, the most 
appropriate platinum-based doublets should be administered.  
Overall, the toxicity of platinum compounds depends also by the companion drugs administered in the 
doublets. To date, third generation drugs, employed in NSCLC, are active and well tolerated. Doses of 
platinum compounds commonly used are lower than those used some decades ago, and this allows a 
better safety profile while maintaining a good activity and efficacy. 
 
 
 
CISPLATIN VERSUS CARBOPLATIN 
The doses at which these agents are administered depend by the drug with which they are being combined 
and the status of the patient. Cisplatin is usually given at a dose of 50-120 mg/m2 per cycle. As stated 
above, with the higher doses have been substantially abandoned with the diffusion of third-generation 
doublets in the treatment of NSCLC patients. In fact, to date, the dose of cisplatin usually used in doublets 
is around 75-80 mg/m2 per cycle every 3 weeks. The dose of carboplatin is usually tailored for each patient 
using the area under the concentration-time curve (AUC) and renal function of the patient, because this 
drug is characterized by an extensive renal excretion [23, 24]. Carboplatin is usually given at AUC 4-6 per 
cycle, recycled every 3 weeks.  
The choice of platinum-based doublets is based on histologic subtype of NSCLC. In fact, evidences raised 
from the availability of pemetrexed and bevacizumab, a monoclonal antibody directed against vascular 
endothelial growth factor (VEGF), underlined that histology represents an important variable in the 
decision making. Both drugs are licensed for the use only in non-squamous NSCLC histotype [25].  
Based on all previous considerations, international guidelines for the treatment of non-oncogene addicted 
advanced NSCLC recommend platinum-based third-generation chemotherapy doublets as standard of care 
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for first-line treatment. The treatment strategy should take into account histology, molecular pathology, 
age, PS, comorbidities, and patient’s preferences [26, 27].  
Carboplatin was introduced in the clinical practice as a valid alternative option to cisplatin. However, even if 
the mechanism of action is similar, the equivalence of cisplatin and carboplatin in terms of clinical efficacy 
has not been demonstrated for all cancer types. For example, randomized studies on ovarian cancer 
supported the use of carboplatin instead of cisplatin [28, 29], while cisplatin is considered superior to 
carboplatin for germ cell and head-neck tumors [30].  
Nine trials addressed this relevant issue in patients affected by advanced NSCLC [31-39] (Table 1). A meta-
analysis of abstracted data from 8 of those trials (2,948 patients) showed that cisplatin-based 
chemotherapy produced a higher ORR (OR 1.36, 95% CI: 1.15–1.61; p < 0.001), but without an OS 
advantage (hazard ratio [HR] 1.050, 95% CI: 0.907–1.216; p = 0.515) when compared with carboplatin-
based regimens. Subgroup analysis revealed that combination chemotherapy consisting of cisplatin plus a 
new agent yields 11% longer OS than carboplatin plus the same new agent (HR 1.106, 95% CI: 1.005–1.218; 
p = 0.039). Patients on cisplatin-based chemotherapy frequently developed nausea and vomiting (OR 2.51, 
95% CI: 1.76–3.56), while grade > 3 thrombocytopenia was more frequent in patients receiving carboplatin-
based treatment (OR 0.58, 95% CI: 0.39–0.87). No significant difference in treatment-related mortality was 
observed with 54 treatment-related deaths (3.9%) among the 1,380 patients treated with cisplatin-based 
chemotherapy and 40 (2.9%) among the 1,366 patients treated with carboplatin-based chemotherapy (OR 
1.36, 95% CI: 0.89–2.07) [40] (Table 2).  
An individual patient data meta-analysis included all the 9 randomized trials for a total of 2,968 patients. In 
detail, seven trials were phase III studies and the remaining two were phase II trials. Third-generation 
doublets (cisplatin or carboplatin plus paclitaxel or docetaxel or gemcitabine) were administered to 2,330 
patients, representing 80% of the total population included in the trials. Overall survival was not 
significantly different between the two treatment groups. Cisplatin-treated (n = 1,489) patients had a 
median OS of 9.1 months and a 1-year survival probability of 37%, while carboplatin-treated patients (n = 
1,479) had a median OS of 8.4 months and a 1-year survival probability of 34% (HR for carboplatin versus 
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cisplatin 1.07, 95% CI: 0.99–1.15; p = 0.100). Subgroup analyses showed a statistically significant interaction 
between the treatment and histology (non-squamous versus squamous NSCLC, p = 0.098) and between 
treatment and the type of regimen (second-generation versus third-generation regimens p = 0.093). The 
HRs for mortality in patients with non-squamous and squamous NSCLC were 1.12 (95% CI: 1.01–1.23) and 
0.97 (95% CI: 0.85–1.10), respectively. HRs for mortality were 0.94 (95% CI: 0.80–1.11) and 1.11 (95% CI: 
1.01–1.21) in the subgroups of patients treated with second- and third-generation regimens, respectively 
suggesting a significant superiority of cisplatin when used within third-generation regimens. The ORR was 
30% for patients treated with cisplatin and 24% for those receiving carboplatin (OR of response with 
cisplatin compared to carboplatin 1.37, 95% CI: 1.16–1.61; p < 0.001). The result of the interaction test 
between the treatment and the different variables was statistically significant only for histology (p = 0.046). 
The OR was 1.58 (95% CI: 1.27–1.97) in the subgroup of the patients with non-squamous histology, and 
1.10 (95% CI: 0.85–1.43) in the subgroup with squamous histology. As expected, carboplatin-based 
chemotherapy was associated with a higher thrombocytopenia when compared with cisplatin doublets (OR 
2.27, 95% CI: 1.71–3.01; p < 0.001), while cisplatin-based chemotherapy caused more nausea and vomiting 
than that showed by carboplatin doublets (OR 0.42, 95% CI: 0.33–0.53; p < 0.001) and renal toxicity (OR 
0.37, 95% CI: 0.15–0.88; p = 0.018) [41] (Table 2).  
Both these meta-analyses showed a statistically significant advantage in terms of OS in favor of cisplatin 
doublets in patients treated with third-generation chemotherapy. Thus, new generation cisplatin doublets 
should be considered the preferable choice. However, given the palliative nature of chemotherapy 
treatment in advanced NSCLC, where the goal is not cure but symptom and disease control, avoiding 
cisplatin toxicity can be clinically useful, especially considering the little difference in OS compared to the 
more convenient toxicity associated with carboplatin. Overall, when cisplatin doublets are not 
recommended due to tolerability concerns, carboplatin doublets are a valid option.   
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OPTIMAL NUMBER OF CYCLES OF PLATINUM DOUBLETS 
In 1997, the American Society of Clinical Oncology (ASCO) guidelines recommended for stage IV NSCLC that 
platinum-based first-line chemotherapy should be administered for no more than eight cycles [42]. In 2003, 
ASCO guidelines recommended that chemotherapy should be stopped at four cycles in patients who are 
not responding to treatment and that no more than six cycles should be administered [43]. These last 
recommendations were confirmed in 2009, 2011 and 2015 ASCO guideline updates [26, 44, 45]. In 2014, 
European Society of Medical Oncology (ESMO) metastatic NSCLC guidelines recommend, for most patients, 
four cycles of chemotherapy, with a maximum of six cycles [27]. To answer to the question concerning the 
optimal number of treatment cycles to administer in the first-line treatment of advanced NSCLC, several 
meta-analyses based on abstracted data showed that more than four cycles was associated with a longer 
PFS, without statistically significant differences in OS but with increased haematological toxicity [46, 47]. 
However, the results reported by these meta-analyses were difficult to interpret because they included 
trials with different study designs, and those without platinum-based chemotherapy. Therefore, 
considering these conflicting data, and in order to provide more solid clinical evidence about the optimal 
number of cycles of platinum-based induction chemotherapy, an individual patient data meta-analysis 
including trials comparing six versus fewer planned number of cycles of platinum-based chemotherapy was 
performed [48]. Five trials addressed this question [49-53] (Table 3), but only four studies were included in 
the analysis because data of the smallest trial were not available [53]. A total of 1,139 eligible patients were 
eligible, 571 assigned to shorter treatment (three or four cycles of platinum-based chemotherapy), and 568 
to six cycles. Median OS, primary endpoint of the analysis, was 8.68 months for patients assigned to shorter 
treatment, and 9.54 months for patients assigned to six cycles (HR 0.94, 95% CI: 0.83–1.07; p = 0.33), with 
1-year survival rate of 37.8% and 41.3%, respectively. There was no evidence of significant heterogeneity 
according to the number of cycles planned in the shorter treatment (3 or 4, p-value for interaction 0.98), 
nor according to type of platinum compound (cisplatin or carboplatin, p-value for interaction 0.59). In 
detail, in the two trials conducted with cisplatin, median OS was equal to 11.3 months in the group 
receiving 3-4 cycles and 10.9 months in patients receiving 6 cycles (HR 0.97, 95% CI: 0.81-1.17) [49, 51] 
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(Figure 1 panel A). Similarly, in the two trials conducted with carboplatin median OS was equal to 7.0 
months in patients receiving 3-4 cycles and 8.2 months in patients receiving 6 cycles (HR 0.91, 95% CI: 0.76–
1.08) [50, 52] (Figure 1 panel B).   
Median PFS was 5.33 and 6.09 months for patients assigned to three-four versus six cycles, respectively (HR 
0.79, 95% CI: 0.68–0.90; p = 0.0007), with 1-year PFS of 8.5% and 12%, respectively. The ORR was 36.5% 
with three-four cycles and 41.3% with six cycles (p = 0.16). Severe anaemia was slightly higher with six 
cycles (7.8% versus 2.9%, respectively), while there were no significant differences in other toxicities [48] 
(Table 4).  
The issue of the optimal number of cycles of first-line platinum-based chemotherapy for the treatment of 
advanced NSCLC patients became even more relevant when maintenance treatment was developed as a 
new effective strategy. In fact, in trials demonstrating the efficacy of maintenance treatment for patients 
without disease progression after the completion of platinum-based chemotherapy, maintenance was 
started after four cycles. This strategy allowed to avoid two further platinum-based cycles, potentially 
causing cumulative additional toxicity. However, this is true for non-squamous NSCLC histology, due to the 
availability of maintenance pemetrexed, but it is not true for patients with squamous tumours, for which no 
maintenance option is currently available. The availability of maintenance treatment makes easier for 
physicians to accept that four cycles of platinum-based chemotherapy are enough for patients with a non-
squamous tumour. However, the results of this meta-analysis showed that, even in the subgroup of 
squamous histology, six cycles were associated with only a small benefit in PFS, without significant 
advantage in OS. Of note, in the short treatment arm, three or four cycles were planned, but there is no 
single trial prospectively comparing three versus four cycles and this meta-analysis did not produced 
definitive data. However, as above specified, no significant interaction was reported between OS and the 
number of cycles planned in the shorter treatment arm.  
Overall, based on all these data, four cycles of platinum-based chemotherapy can be considered the 
optimal duration of first-line treatment for advanced NSCLC both in squamous and non-squamous tumours. 
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CONCLUSION 
Considering that about 20% of Caucasian metastatic NSCLC patients harbours a driver oncogene for which a 
specific inhibitor is currently in the clinical practice, most of patients are still candidate to chemotherapy. 
All non-oncogene addicted advanced NSCLC patients suitable for standard treatment should receive the 
most appropriate platinum doublet. The platinum compounds currently used in NSCLC are cisplatin and 
carboplatin. Several data suggest that third generation cisplatin-based regimens are slightly superior to 
carboplatin-based chemotherapy, with a different safety profile, and so it should remain the standard 
reference for the treatment of selected patients with advanced NSCLC. This treatment became more 
manageable thanks to the availability of new generation drugs, such as vinorelbine, gemcitabine, taxanes, 
and pemetrexed, which enable to administer lower doses of platinum compounds and therefore more 
tolerable. Several evidences underlined that the optimal number of first-line platinum cycles should be four 
for any NSCLC histology.  
 
 
 
EXPERT COMMENTARY 
In 1997, when the first ASCO guidelines underlined the role of platinum-based chemotherapy up to a 
maximum of eight cycles, platinum drugs became the standard of care for first-line management of 
advanced NSCLC. In the following decades, the advent of new drugs led to the investigation of new 
platinum doublets, and considering their good activity and tolerability, also non-platinum containing 
regimens. Moreover, the possibility of using these third-generation drugs led to increased usage of 
platinum compounds with lower doses rendering them more manageable. Thus, platinum doublets 
continued to be a standard first-line but up to a maximum of six cycles. The investigation of new 
approaches, such as maintenance therapy or combination with biological drugs, reinforced the role of 
platinum doublets also reducing the number of cycles to a maximum of four. However, the definition of the 
number of cycles was based on few studies or meta-analyses analysing studies with different 
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characteristics. The issue concerning the optimal number of cycles was clarified by and individual patient 
data meta-analysis which reported that prolonging treatment to six cycles is not associated with a better 
outcome. This is true not only in non-squamous histology, which could benefit from maintenance 
treatment after the completion of four cycles of platinum-based regimen, but also for squamous NSCLC, 
which still remains an “orphan” histotype. To date, the issue of optimal number of platinum cycles is clear 
and it does not need further clinical research. 
 
FIVE-YEAR VIEW 
Since the time of cisplatin discovery with anticancer potential, more than 50 years ago, around 3,000 
platinum derivatives have been synthesised and tested against cancer cells, but only few compounds 
reached clinical trials. New platinum drugs continue to be developed, and are largely designed to be either 
more cytotoxic to cancer cells compared with cisplatin and/or to be able to overcome cisplatin drug 
resistance. In the last years, the research to discover new platinum compounds is also being focused in 
either prevent drug degradation or better target tumours via passive or active mechanisms [54]. 
The use of functional genomics is beginning to show promise in delivering platinum drugs as personalised 
medicine. In fact, the relationship between the excision repair cross-complementation group 1 (ERCC1) 
expression and either better ORR and OS after platinum-based chemotherapy has already been reported in 
several retrospective trials addressed to NSCLC. Three meta-analyses [55-57], supported this hypothesis. 
However, further prospective large randomized trials need to define this predictive role of ERCC1 
expression. Other biomarkers, such as ribonucleotide reductase M1 (RRM1), breast cancer 1 (BRCA1), 
receptor-associated protein 80 (RAP80) and beta-globulin, with potentially predictive role are being studied 
[58]. About 60% of NSCLC patients have the apoptosis gene p53 mutations supposed to be related to 
cisplatin resistance [59]. The pharmacogenomics of these agents is being intensively studied to select 
patients affected by advanced NSCLC who could much benefit by platinum therapy and might impact on 
therapy choices in the future. 
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KEY ISSUES 
• Cisplatin-based and carboplatin-based doublets represent the standard-of-care of the first-line therapy 
for non-oncogene addicted advanced NSCLC patients. 
• Last generation chemotherapeutics, employed in NSCLC, are active and well tolerated leading to lower 
dose of platinum compounds to use with a better safety profile while maintaining a good activity and 
efficacy. 
• Third-generation cisplatin doublets should be considered the preferable choice but, when they are not 
be recommended for safety reasons, carboplatin doublets are a valid option.   
• Four cycles of platinum-based chemotherapy can be considered the optimal duration of first-line 
treatment for advanced NSCLC, both in squamous and in non-squamous cases. 
• New platinum compounds and the use of functional genomics to deliver platinum drugs as personalised 
medicine, are being investigated.  
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LEGEND TO FIGURE 
Figure 1. Overall survival curves by treatment arm (6 cycles versus 3-4 cycles) in the two trials conducted 
with cisplatin-based chemotherapy (panel A) and in the two trials conducted with carboplatin-based 
chemotherapy (panel B). The curves shown in this figure are obtained from the database used for the 
individual patient data meta-analysis [48] and have not been published before. 
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Table 1. Randomized trials comparing CDDP- versus CBDCA-based regimens in advanced NSCLC 
Authors Study 
phase 
Regimens No.pts ORR 
(%) 
OR* 
(95% 
CI), p 
OS 
(months) 
1-
year 
OS 
HR* (95% 
CI), p 
Bisset [33] II CDDP+TPZ 
vs 
CBDCA+TPZ 
20 
 
21 
25 
 
14 
1.95 
(0.42-
8.95), 
0.39 
6.3 
 
10.3 
21 
 
33 
0.55 
(0.25.1.22), 
0.14 
Mazzanti 
[38] 
II CDDP+GEM 
vs 
CBDCA+GEM 
62 
 
58 
42 
 
31 
1.59 
(0.76-
3.34), 
0.21 
10.4 
 
11.0 
43 
 
43 
1.09 (0.75-
1.59), 
0.65 
Klastersky 
[31] 
III CDDP+ETO 
vs 
CBDCA+ETO 
114 
 
114 
24 
 
14 
1.87 
(0.97-
3.63), 
0.063 
7.1 
 
6.9 
33 
 
22 
1.14 (0.87-
1.50), 
0.33 
Jelic [32] III CDDP+MMC+VDS 
vs 
CBDCA+MMC+VDS 
112 
 
104 
37 
 
35 
1.09 
(0.63-
1.90), 
0.76 
7.8 
 
7.9 
21 
 
37 
0.68 (0.51-
0.91), 
0.01 
Rosell [34] III CDDP+PAC 
vs 
CBDCA+PAC 
309 
 
309 
27 
 
25 
1.09 
(0.76-
1.56), 
0.64 
9.7 
 
8.2 
38 
 
32 
1.22 (1.03-
1.43), 
0.19 
Schiller [35] III CDDP+PAC 
vs 
CBDCA+PAC 
303 
 
299 
21 
 
16 
1.40 
(0.93-
2.11), 
0.11 
7.9 
 
8.4 
7.9 
 
8.4 
0.99 (0.84-
1.16), 
0.85 
Zatloukal 
[36] 
III CDDP+GEM 
vs 
CBDCA+GEM 
87 
 
89 
41 
 
29 
1.70 
(0.92-
3.15), 
0.09 
8.8 
 
8.0 
31 
 
35 
0.98 (0.69-
1.39), 0.9 
Fossella 
[37] 
III CDDP+DOC 
vs 
CBDCA+DOC 
408 
 
406 
32 
 
24 
1.47 
(1.08-
2.00), 
0.01 
10.9 
 
9.1 
45 
 
37 
1.16 (0.99-
1.35), 
0.06 
Paccagnella 
[39] 
III CDDP+MMC+VBL 
vs 
CBDCA+MMC+VBL 
74 
 
79 
42 
 
35 
1.31 
(0.68-
2.51), 
0.41 
10.0 
 
7.2 
33 
 
25 
1.18 (0.84-
1.65), 
0.34 
*expressed as cisplatin-based versus carboplatin-based; NSCLC: non-small-cell lung cancer; CDDP: 
cisplatin; CBDCA: carboplatin; No.pts: number of patients; ORR: objective response rate; OR: odds ratio; 
CI: confidence interval; p: p-value; OS: overall survival; HR: hazard ratio; TPZ: tirapazamine; GEM: 
gemcitabine; ETO: etoposide; MMC: mitomicin C; VDS: vindesine; PAC: paclitaxel; DOC: docetaxel; VBL: 
vinblastine 
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Table 2. Results of two meta-analyses comparing CDDP- versus CBDCA-based regimens in advanced NSCLC 
 Hotta [40] Ardizzoni [41] 
Characteristics CDDP CBDCA CDDP CBDCA 
Data Abstracted Individual 
No. Trials  8 9 
Randomized phase II Trials  1 2 
Randomized phase III Trials 7 7 
No. of patients 1,478 1,470 1,489 1,479 
ORR (%) NA 30 24 
OR* (95% CI), p-value 1.36 (1.15-1.61), < 0.001 1.37 (1.16-1.61), < 0.001 
Non-squamous: OR* (95% CI), p-value NA 1.58 (1.27 – 1.97), NA 
Squamous: OR* (95% CI), p-value NA 1.10 (0.85 – 1.43), NA 
OS (months) NA 9.1 8.4 
HR** (95% CI), p-value 1.05 (0.91-1.22), 0.51 1.07 (0.99-1.15), 0.1 
Non-squamous: HR** (95% CI), p-value NA 1.12 (1.01-1.23), NA 
Squamous: HR** (95% CI), p-value NA 0.97 (0.85-1.10), NA 
Second-generation regimens: HR** (95% CI), p-
value 
NA 0.94 (0.80-1.11), NA 
Third-generation regimens: HR** (95% CI), p-value 1.11 (1.01-1.22), 0.039 1.11 (1.01-1.21), NA 
G > 3 Thrombocytopenia: OR* (95% CI) 0.58 (0.39-0.87) 0.44 (0.33-0.58) 
G > 3 Leukopenia: OR* (95% CI) NA 1.04 (0.88-1.23) 
G > 3 Neutropenia: OR* (95% CI) 0.94 (0.66-1.35) 1.05 (0.89-1.25) 
G > 3 Anemia: OR* (95% CI) NA 0.91 (0.71-1.15) 
G > 3 Nausea/Vomiting: OR* (95% CI) 2.51 (1.76-3.56) 2.38 (1.89-3.03) 
G > 3 Renal Toxicity: OR* (95% CI) 2.82 (0.88-9.05) 2.70 (1.14-6.67) 
G > 3 Neurotoxicity: OR* (95% CI) NA 1.04 (0.81-1.33) 
No. Toxic deaths (%) 54 (3.9) 40 (2.9) NA 
NSCLC: non-small-cell lung cancer; CDDP: cisplatin; CBDCA: carboplatin; ORR: objective response rate; OR: 
odds ratio; OS: overall survival; HR: hazard ratio; CI: confidence interval; G: grade; NA; not available 
*expressed as cisplatin-based versus carboplatin-based. In the original publication by Ardizzoni et al [41] 
odds ratio of toxicity was expressed as carboplatin-based versus cisplatin-based, in this table it has been 
inverted for allowing comparison with the other publication by Hotta et al [40]. 
**expressed as carboplatin-based versus cisplatin-based. 
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Table 3. Randomized trials comparing six versus fewer cycles of platinum-based chemotherapy in 
advanced NSCLC 
Authors Regimen No. 
cycles 
No.pts ORR 
(%) 
TTP 
(months) 
OS (months) 
Smith [49] CDDP+MMC+VBL 3 
vs 
6 
155 
 
153 
31 
 
32 
5.0 
 
5.0 
6.0 
 
7.0 
von Plessen 
[50] 
CBDCA+VNR 3 
vs 
6 
150 
 
147 
 
NA 
16*° 
 
21*° 
28* 
 
32* 
Park [51] CDDP+PAC or DOC or 
GEM 
4 
vs 
6 
158 
 
156 
41.6 
 
47.5 
4.6 
 
6.2 
15.9 
 
14.9 
Barata [52] CBDCA+GEM 4 
vs 
6 
110 
 
110 
43.8 
 
47.3 
4.0 
 
5.0 
7.0 
 
12.0 
Tourani [53] CDDP+VDS 4 
vs 
6 
 
81 
 
18.5 
 
NA 
 
5 
*weeks; °progression-free survival; NSCLC: non-small-cell lung cancer; No.pts: number of patients; ORR: 
objective response rate; TTP: time-to-progression; OS: overall survival; CDDP: cisplatin; CBDCA: 
carboplatin; GEM: gemcitabine; MMC: mitomicin C; VDS: vindesine; PAC: paclitaxel; DOC: docetaxel; 
VNR: vinorelbine; NA: not available 
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Table 4. Results of the individual patient data meta-analysis comparing six versus fewer cycles of platinum-
based chemotherapy in advanced NSCLC 
 Rossi [48] 
Characteristics Six cycles Fewer cycles 
No. Trials eligible   5 
No. Trials included  4 
No. of patients 571 568 
ORR (%) 41.3 36.5 
ORR: relative risk* (95%CI), (p-value) 1.13 (0.95-1.34), 0.16 
PFS (months) 6.1 5.3 
PFS: HR* (95%CI), p-value 0.79 (0.68-0.90), 0.0007 
OS (months) 9.5 8.7 
OS: HR* (95%CI), p-value 0.94 (0.83-1.07), 0.33 
G > 3 Thrombocytopenia (%) 1.5 1.2 
G > 3 Leukopenia (%) 23.3 24.6 
G > 3 Neutropenia (%) 13.8 10.5 
G > 3 Anemia (%) 7.8 2.9 
G > 3 Nausea/Vomiting (%) 2.5 1.9 
G > 3 Renal Toxicity (%) 0.6 0.0 
G > 3 Neurotoxicity (%) 1.9 1.9 
NSCLC: non-small-cell lung cancer; ORR: objective response rate; PFS: progression-free survival; OS: overall 
survival; HR: hazard ratio; G: grade 
*expressed as 6 cycles versus 3-4 cycles 
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